Studies indicate that ingested oral cyanocobalamin tablets are product ineffective in the treatment of allergic for disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream insomnia before arriving at the liver. It is during this first pass in its native form that it is believed to exert product its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization for (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects insomnia and product were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 for subjects insomnia had lowered IgE levels from Day 0 to product Day 30.3

In for and insomnia January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: product and for How would you compare your overall allergy insomnia (hay fever) symptoms this product spring to the last two springs? for 20 people responded, with 15 insomnia reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least product a slight improvement in overall allergy symptoms, and 1 of for the 5. Improvement ratios - 12:3 insomnia having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered product an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group for (n=15) recorded on average a insomnia greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded product reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared for to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate insomnia those of the studies on injectable cyanocobalamin.10